Drug-eluting bioresorbable vascular scaffolds (BVSs) are as good as traditional drug-eluting metallic stents for arterial healing in ST-segment elevated myocardial infarction (STEMI) patients, results from the ABSORB -STEMI TROFI II trial show.
Valsartan/sacubitril (formerly LCZ696), recently approved by the US Food and Drug Administration for treating heart failure, may also be beneficial for reducing blood pressure (brachial and central aortic pressure) as well as arterial stiffness compared with angiotensin receptor blocker olmesartan.
Gene transfer therapy to correct an enzyme abnormality did not improve the rate of recurrent hospitalization due to heart failure or terminal events in patients with moderate to severe heart failure, the CUPID 2* study showed.
Individuals with chronic ischaemic heart disease (IHD) and a small left ventricle and thick myocardium demonstrated higher levels of cardiac remodelling as opposed to those with a large ventricle and thin myocardium, contrary to the prevailing understanding, according to the DOPPLER-CIP study.
Electrical isolation of the left atrial appendage (LAA) by radiofrequency ablation improves outcomes in patients at risk of stroke due to long-standing persistent atrial fibrillation (AF) compared with standard ablation alone, the BELIEF trial has shown.
A lead-free pacemaker implanted directly into the right ventricle proved safe and effective in patients who need permanent single-chamber ventricular pacing, according to results from the LEADLESS II trial.
Data from the ELIXA* trial on lixisenatide and a new subgroup analysis of the TECOS** trial on sitagliptin, both type 2 diabetes (T2D) therapies, confirmed no associated increased risk of cardiovascular complications, even in patients with a history of acute coronary syndrome (ACS) or existing cardiovascular disease (CVD).
A diagnostic strategy using computed tomographic angiography with fractional flow reserve (CTA/FFRCT) assessment reduces the need for invasive coronary angiography (ICA) in patients with suspected coronary artery disease (CAD) , the PLATFORM* study has shown.
Adding spironolactone to a guideline-recommended three-drug combination regimen provides the most effective blood pressure (BP) control for patients with resistant hypertension, results of the PATHWAY-2 trial have shown.
COX-2 inhibitors and nonselective NSAIDs are associated with an equally low risk of cardiovascular (CV) events and gastrointestinal (GI) complications in patients who take them regularly for up to 6 years, a study presented at the European Society of Cardiology (ESC) Congress 2015 has shown.
A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated.
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.